Plaidoyer pour l’accès équitable aux nouvelles technologies de santé : le cas du Kymriah® (notice n° 1005245)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04299cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250125135127.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Brigand, Théau |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Plaidoyer pour l’accès équitable aux nouvelles technologies de santé : le cas du Kymriah® |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 29 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les brevets ont été pensés comme un modèle d’incitation à la recherche en conférant des monopoles temporaires permettant de tirer profit d’une invention. Sur le marché pharmaceutique, des brevets immérités sont octroyés, autorisant les firmes à bénéficier de monopoles illégitimes et exiger des prix élevés. Ces abus se font aux dépens de l’accès aux soins et de l’équilibre financier des systèmes de santé.Ils ont été démontrés sur les traitements contre le VIH et les hépatites, ils sont aussi pratiqués sur les traitements anticancéreux à l’image des traitements CAR-T (Chimeric Antigen Receptor T-Cell), dont les prix, particulièrement élevés, sont un défi pour les systèmes de santé.Médecins du Monde et Public Eye, deux associations plaidant pour l’accès aux traitements, ont souhaité interroger la brevetabilité des traitements CAR-T, et renforcer la capacité des systèmes de santé à négocier des prix plus justes. Ces organisations ont introduit une opposition au brevet contre un de ces traitements, le Kymriah® (tisagenlecleucel).Par cette procédure, ces organisations ont alerté l’opinion publique et les décideurs politiques sur les prix élevés des traitements CAR-T. L’opposition a contraint la firme Novartis et l’Université de Pennsylvanie à demander la révocation du brevet. Cette initiative suggère que celui-ci avait été accordé alors qu’il ne remplissait pas les critères de brevetabilité.Le traitement est couvert par d’autres brevets, cette opposition ne met pas fin au monopole. Elle affaiblit néanmoins la propriété intellectuelle sur ce médicament et renforce les États dans la négociation du prix. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction: Patents have been thought of as an incentive model for research, conferring temporary monopolies to take advantage of an invention. In the pharmaceutical market, unmerited patents are granted, allowing firms to benefit from illegitimate monopolies and demand high prices. These abuses are at the expense of access to care and the financial sustainability of health care systems.These abuses have been demonstrated on treatments for HIV and hepatitis, and are also practiced on anti-cancer treatments such as CAR-T therapies (Chimeric Antigen Receptor T-Cell), whose particularly high prices are a challenge for health systems. Purpose of research: Médecins du Monde and Public Eye, two NGOs advocating on price and access to treatment, wanted to question the patentability of CAR-T treatments as well as to strengthen the capacity of health systems to negotiate fairer prices. These organizations filed a patent opposition against one of these treatments, Kymriah® (tisagenlecleucel). Results: Through this initiative, these organizations alerted public opinion and policy makers on the high prices of CAR-T treatments. The opposition forced Novartis and the University of Pennsylvania to request the revocation of the patent. This action suggests that the patent was granted when it failed to meet the patentability criteria. Conclusions: The treatment is still covered by other patents, this opposition does not end the monopoly. Nevertheless, it weakens the intellectual property on this drug and strengthens the States during price negotiations. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapies cellulaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prix des médicaments |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hématologie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | accès aux soins |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | brevet |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hematology |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | patent |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | access to care |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drug pricing |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cellular therapies |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maguet, Olivier |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Veras, Juliana |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Durisch, Patrick |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 32 | 5 | 2021-03-02 | p. 525-529 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-sante-publique-2020-5-page-525?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-sante-publique-2020-5-page-525?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux